Trushar Patel
@TrusharPatelMD
Followers
1K
Following
414
Media
83
Statuses
815
Vice Chair of Urology | Residency Program Director @USFUrology @UsfHealth | Associate Professor | #UrologicOncology | #GirlDad
Tampa, FL
Joined July 2011
#RoboUroOnc @CityofHopeSurg #Urology fellow, Dr. Ahmad Saeed Imam, @ImamOfUrology, presenting multidisciplinary research efforts at #WSAUA25 @auawest in #prostatecancer & #ilealureter creation. @SalvadorjcMD @BYuhMD @WesleyYipMD @arafflemd @montypal @COHurol @ClaytonLauMD
1
9
24
Proud of our @USFUrology stars — Dr. Joe Balbona, Dr. Alyssa Biollota & Dr. Tyler Cook — finishing their @MoffittNews rotation! Until next time — the future of urology is in great hands. 👏 @AmerUrological @UrologyMatch
0
2
10
Exciting 23 year update from the ERSPC #prostatecancer screening trial from @MoniqueRoobol and team, and a great editorial @VickersBiostats. NND is down to 12 and still falling! And the benefit:harm ratio would be even better w/ modern screening/dx/tx pathways.
At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: https://t.co/DTw9NcUFJM Editorial: Early Detection of Prostate Cancer —
5
31
108
New out in @TheLancetOncol with Ted Schaeffer: https://t.co/mdc6hQNpUN "Revisiting prostate cancer active surveillance candidacy" A close look at the fallacy and risks of active surveillance (AS) in unselected intermediate risk (IR) men. @wandering_gu @TylerSbrt
pubmed.ncbi.nlm.nih.gov
Revisiting prostate cancer active surveillance candidacy
2
19
67
De escalated therapy is safe for stage IIA-IIB seminoma! ✅No recurrence since initial presentation in 2021. ✅No severe toxicity. ✅Secondary malignancies only outside of radiotherapy fields. Long term outcomes of SAKK 01/10 by @Alex_Papachris at #ESMO2
2
48
100
🚨Important update from ProtecT #ProstateCancer trial after central pathology review 1️⃣ Which early PCa need treatment? Which do not? 2️⃣ For “bad” early PCa, do RP or RT prevent long-term (15y) metastasis? 🧵1/ @OncoAlert @urotoday @PCF_Science @JAMAOnc @Uroweb @AmerUrological
1/2 Just published in @JAMAOnc: 15-year outcomes of Active Monitoring, Surgery, and Radiotherapy for cribriform-positive and cribriform-negative prostate cancer in the ProtecT trial. Secondary analysis based on centralised biopsy review🔬 Article:
7
75
150
NEW #Urology Care Podcast! Listen as our guests, @Scarps_kristen and @TrusharPatelMD, debunk myths about non-muscle invasive bladder cancer treatment. Learning more may help you speak up about which option is right for you! Full podcast here: https://t.co/n0mmdvuL5z
0
1
1
Coming from the #ASTRO25 Plenary? Our NEW episode is now available to deep dive into the results of RadComp and NRG-GU005 that were just reported! Listen: https://t.co/OSMLZzmDzK
@SameerKeoleMD @shannonmacdonmd @ellis_rod
1
6
10
A fantastic poster presentation by @zcons on "patient perspectives on Attributes SP vs MP" @TrusharPatelMD, at the Robotic Bladder/Prostate cancer session moderated by @BristolWhiles Josh Heiman Yoshiyuki Kojima #WCET25
@Endo_Society 💯
0
4
7
On September 9, 2025, the Food and Drug Administration approved gemcitabine intravesical system (Inlexzo, Janssen Biotech, Inc.) for adults with BCG - unresponsive NMIBC with CIS with or without papillary tumors. Also known as TAR-200: this gemcitabine intravesical system is
4
42
129
Just published! 🙂 Available from https://t.co/AN1ZTRRHB4 Special thanks to Prof. @ThomasPolascik and also to all co-authors for their support and guidance. @JuddMoul @alirezaghoreifi #prostatecancer
0
5
23
**URPS Fellowship at William Beaumont University Hospital 2026-28** 7 faculty; high volume in F/M incontinence, prolapse, SNM, neurourology, IC/CPPS; multidisciplinary women’s center; global surgical rotations, NIH/DoD grants. Contact: priya.padmanabhan@corewellhealth.org or
4
19
49
Our new research Overall: 1% of all births & 3.0% of IVF births had at least 1 parent with a cancer history in US Unassisted conception: 0.5% of mothers & 0.4% of fathers had cancer history IVF conception: 1.2% of mothers & 1.8% of fathers @JNCI_Now
https://t.co/Em2XKU7AA4
academic.oup.com
AbstractBackground. Advances in cancer treatment have led to an increased number of survivors who may subsequently have children. We aim to describe the pr
0
5
19
@UroChrisGuske leaving his fingerprints on the BCG-UR space @AmerUrological programs - Chris is a Superstar @USFHealth MS4 applying this year with unbound potential! Highly recommend giving him a good look 👀 @USFUrology
🚨New in @EurUrolOncol w/ @UrogerliMD “Assessing the Impact of Treatment Timing Protocols in Clinical Trials for BCG-unresponsive NMIBC” BCG-UR trials employ rigid time-to-treatment cutoffs as part of enrollment criteria—but are these needed? 🔗 https://t.co/EMOskBijMz 1/2
0
3
15